Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Blog
-
Incorporating C-Reactive Protein and Lp-PLA2 into Annual Physical Examinations
Incorporating C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 into Annual Physical Examinations
A Evidence-Based Proposal for Enhanced Cardiovascular Risk Assessment
Executive Summary
Cardiovascular disease remains the leading cause of mortality worldwide, with myocardial infarction and stroke accounting for significant morbidity and healthcare costs. This white paper proposes incorporating C-Reactive Protein (CRP) and Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) testing into routine annual physical examinations as evidence-based biomarkers for enhanced cardiovascular risk assessment.
These inflammatory biomarkers provide critical information beyond traditional lipid panels and can identify at-risk individuals who might otherwise be missed by conventional screening methods. The integration of these tests into standard practice represents a paradigm shift toward proactive, prevention-focused cardiovascular care.
-
One-Time Pediatric Screening for Lipoprotein(a): A Paradigm Shift in Cardiovascular Disease Prevention
One-Time Pediatric Screening for Lipoprotein(a): A Paradigm Shift in Cardiovascular Disease Prevention
Executive Summary
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor affecting 20% of the population, conferring up to 3-fold increased risk for cardiovascular events. This white paper proposes implementing one-time pediatric screening for Lp(a) as a cost-effective strategy for early identification of at-risk individuals and implementation of preventive interventions.
Given that Lp(a) levels are primarily genetically determined and remain relatively stable throughout life, a single measurement during childhood can provide lifelong risk stratification information, enabling early lifestyle modifications and targeted therapeutic interventions.
-
C-Reactive Protein as a Universal Screening Biomarker for Autism Spectrum Disorder
C-Reactive Protein as a Universal Screening Biomarker for Autism Spectrum Disorder
A Clinical Implementation White Paper
Executive Summary
Current autism spectrum disorder (ASD) diagnosis relies heavily on subjective behavioral assessments that often delay identification until ages 3-5, missing critical early intervention windows. This white paper proposes implementing C-Reactive Protein (CRP) testing as a universal screening biomarker for ASD, based on emerging evidence linking systemic inflammation to autism pathophysiology.
Research has demonstrated that children with ASD exhibit significantly elevated hs-CRP levels (often exceeding 500 ng/mL compared to normal levels below 1.0 ng/mL), suggesting that inflammatory biomarkers could serve as objective, early screening tools. Combined with existing behavioral screening instruments like the M-CHAT, CRP testing could dramatically improve early detection rates and enable timely intervention.